Radiotherapy for locally recurrent prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 12, 2005, Pages 933-942

  Kirkpatrick, John P ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Prostate cancer; Radiation therapy; Recurrence; Salvage

Indexed keywords

ACETIC ACID; ANDROGEN; BICALUTAMIDE; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE; FLUORINE 18; FLUORODEOXYGLUCOSE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CLINICAL OBSERVATION; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMMUNOSCINTIGRAPHY; INTENSITY MODULATED RADIATION THERAPY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; SALVAGE THERAPY; TREATMENT PLANNING;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 31644432472     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Jemal A. Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393-1401.
3. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633-2636.
4. Swanson GP, Thompson IM, Tangen C, et al. Phase III randomized trial of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). Int J Radiat Oncol Biol Phys. 2005;63(2 suppl 1):S1.
5. Ornstein DK, Colberg JW, Virgo KS, et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology. 1998;52:1047-1054.
6. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163:1632-1642.
7. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
8. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer. 2000;88:2110-2115.
9. Endrizzi J, Seay T. The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. BJU Int. 2000;85:696-698.
10. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998;52:1079-1084.
11. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radio-therapy. Int J Radiat Oncol Biol Phys. 1991;21:941-947.
12. Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003;61:742-747.
13. Freedland S, Humphreys E, Mangold L, et al. Risk of prostate cancer specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
14. Brewster SF, Oxley JD, Trivella. M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 161:1238-1243.
15. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol. 1995;153(3 pt 2):1015-1019.
16. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor bera(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001;19:2856-2864.
17. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F. Nuclear factor-kappa B nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res. 2004;10:8460-8464.
18. D'Amico AV, Whittington R, Malkowicz SB, et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998;160(6 pt 1):2096-2101.
19. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45:831-838.
20. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
21. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
22. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002;20:3206-3212.
23. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy far localized prostate cancer. J Clin Oncol. 2002;20:951-956.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
25. Mosbacher MR, Schiff PB, Otoole KM, et al. Postprostatectomy salvage radiation therapy for prostate cancer: impact of pathological and biochemical variables and prostate fossa biopsy. Cancer J. 2002;8:242-246.
26. Partin A, Pound C, Clemens J, Epstein J, Walsh P. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin N Am. 1993;20:713-725.
27. Lightner D, Lange P, Reddy P, More L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;144:921-926.
28. Foster L, Jajodia P, Fournier G, Jr., Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 1993;149:1024-1028.
29. Sudakoff GS, Smith R, Vogelzang NJ, Steinberg G, Brendler CB. Color Doppler imaging and transrectal sonography of the prostatic fossa after radical prostatectomy: early experience. AJR Am J Roentgenol. 1996;167:883-888.
30. Leventis AK, Sharlat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fassa biopsy findings. Radiology. 2001;219:432-439.
31. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607-611.
32. Sells T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR. imaging. Radiology. 2004;231:379-385.
33. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:941-947.
34. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
35. Cher MI, Bianco FJ Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387-1391.
36. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94:987-996.
37. Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libettino JA. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology. 1998;51:978-984.
38. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284-289.
39. Seltzer MA, Barbaric Z, Belldegrun. A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322-1328.
40. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715-1721.
41. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117.
42. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol. 1998;159:347-356.
43. Kotzerke J, Volkmer B, Neumaier B, Gschwend J, Hautmann R. Reske S. Carbon-11 acetate positron emission tomography can detect recurrence of prostate cancer. Eur J Nucl Med. 2002;29:1380-1384.
44. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
45. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
46. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997;37:1043-1052.
47. Trapasso J, deKernion J, Smith R. Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-1825.
48. Partin A, Pearson J, Landis P, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649-659.
49. Patel A, Dorey F, Franklin J, DeKernion J. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445.
50. Scardino P, Anscher M, Babaian R. et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer. Jenkinstown, PA: National Comprehensive Cancer Network, 2004. Version 1.
51. Schild SE. Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy. Int J Cancer. 2001;96:94-98.
52. Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys. 1995;33:37-43.
53. Elias S, Parker RG, Gallardo, D, Law J. Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate. Am J Clin Oncol. 1997;20:120-124.
54. Bolla M, Van Poppel H, Van Cangh P, et al. Does post-operative radiotherapy (P-XRT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? Proc Am Soc Clin Oncol. 2004,23:382.
55. Halperin E, Schmidt-Ullrich R, Perez C, Brady L. Overview and basic science of radiation oncology. In: Perez C, Brady L, Halperin E, Schmidt-Ullrich R, eds. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:1-95.
56. Anscher MS. Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution? Int J Radiat Oncol Biol Phys. 1996;34:745-747.
57. Van Cangh P, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol. 1998;159:164-166.
58. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (FORTC trial 22911). Lancet. 2005;366:572-578.
59. Anscher MS. Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 2004;291:1380-1382.
60. Wu A, Whittemore A, Kolonel L, et al. Serum androgens and sex hormonebinding globulins in relation to lifestyle factors in older African-American, White, and Asian men in the United States and Canada. Cancer Epidemiol Biomark Prev. 1995;4:735-741.
61. Zelefsky M, Aschkenasy E, Kelsen S, Leibel S. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:327-333.
62. Medini E, Medini I, Reddy P, Levitt S. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer. 1996;78:1254-1259.
63. Schild S, Buskirk S, Wong W, et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 1996;156:1725-1729.
64. Kaplan I, Bagshaw M. Serum prostate-specific antigen after post prostatectomy radiotherapy. Urology. 1992;39:401-406.
65. Crane C, Rich T, Read P, Sanfilippo N, Gillenwater J, Kelly M. Preitradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys. 1997;39:681-686.
66. Anscher MS, Prosnitz LR. Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys. 1989;17(5):953-958.
67. Vander Kooy M, Pisnasky T, Cha S, Blute M. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997;49:65-70.
68. Syndikus I, Pickle, T, Kostashuk E, Sullivan L. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol. 1996;155-1983-1986.
69. MacDonald OK, Schild SE, Vora S, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology. 2004;64:760-764.
70. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiother Oncol. 2005;74:163-167.
71. Cadeddu J, Partin A. DeWeese T, Walsh P. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 1998;159:173-178.
72. Leventis AK, Shariat SF, Kattan MW, Butter EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030-1039.
73. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
74. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate cardnoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
75. Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Urology. 1999;54:495-502.
76. Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology. 2004;64:976-981.
77. Wu J, King S, Montana G, McKinstry C, Anscher M. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995;32:317-323.
78. Morris M, Dallow K, Zeitman A, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer Int J Radiat Oncol Biol Phys. 1997;38:731-736.
79. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol. Phys. 2000;48:369-375.
80. Pisansky T, Kozelsky T, Myers R, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163:845-850.
81. Valicenti F. Gomella L, Ismail M, Mulholland S, Petersen R, Corn B. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:501-506.
82. Do T, Parker R, Do C, Tran L, Do L, Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am. 1998,4:324-330.
83. Duchesne GM, Dowling C, Frydenberg M, et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology. 2003;61:179-183.
84. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO96-02/AUO AP 09/ 95). J Clin Oncol. 2005;23(16S part I of II):381s.
85. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51-60.
86. Kalapurakal JA, Huang CF, Neriamparampil MM, et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;54:1047-1054.
87. Nudell D, Grossfeld G, Weinberg V, Roach III M, Carroll P. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology. 1999;54:1049-1057.
88. Pacholke HD, Wajsman Z, Algood CB, Morris CG, Zlotecki RA. Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival. Urology. 2004;64:982-986.
89. Peschel R, Robnett T, Hesse D, et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int J Cancer (Radiat Oncol Invest). 2000;90:29-36.
90. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:755-763.
91. Tsien C, Griffith KA, Sandler HM, et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003;62:93-98.
92. Vilicenti R, Gomella L, Ismail M, et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology. 1998;52:1034-1040.
93. Vicini F, Ziaja E, Kestin L, et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999;54:111-117.
94. Mayer R, Pummer K, Quehenberger F, Mayer E, Fink L, Hackl A. Postprostatectomy radiotherapy for high-risk prostate cancer. Urology. 2002;59:732-739.
95. Hagan M, Zlotecki R, Medina C, Tercilla O, Rivera I, Wajsman Z. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:329-340.
96. Cozzarini C, Bolognesi A, Ceresoli GL, et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys. 2004;59:674-683.
97. Garg M, Tekyi-Mensah S, Bolton S, et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 1998;51:998-1002.
98. Hudson M, Catalona W. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol. 1990;143:1174-1177.
99. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A. Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483-489.
100. Keisch M, Perez C, Grigsby P, Bauer W, Catalona W. Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels. Int J Radiat Oncol Biol Phys. 1990;19:1503-1506.
101. Lange P, Lightner D, Medini E, Reddy P, Vessella R. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 1990;144:927-932.
102. Liauw SL, Webster WS, Pistenmaa DA, Rochrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003;61:1204-1210.
103. Link P, Freiha F, Stamey T. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol. 1991;145:532-534.
104. Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy, J Urol. 2003;170:1833-1837.
105. McCarthy J, Catalona W, Hudson M. Effects of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol. 1994;151:1575-1578.
106. Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:600-609.
107. Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients. Urology. 2003;62:503-507.
108. Kamat AM, Babaian K, Cheung MR, et al. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol. 2003;170:1860-1863.
109. Choo R, Hruby G, Hong J, et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys. 2002;52:674-680.
110. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology. 1993;42:283-291.
111. Wiegel T, Bressel M, Carl UM. Adjuvant radiotherapy following radical prostatectomy - results of 56 patients. Eur J Cancer. 1995;31A:5-11.
112. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;41:735-740.
113. King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys. 2004;59:341-347.
114. Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002;60:281-287.